<DOC>
	<DOCNO>NCT00054743</DOCNO>
	<brief_summary>This study determine whether blood level anti-HIV medicine nevirapine different HIV-infected patient United States patient Uganda . People world take medication treat HIV infection . These medicine work well people others , cause harmful side effect people others . These difference may relate variation much drug reach blood . Differences drug blood level among people various area world may attribute difference diet , state health , ability absorb medicine stomach , ability eliminate drug body , brand medicine take . This study help scientist learn whether difference blood level HIV medicine important determine well drug work different patient population . HIV-infected patient 18 year age old United States Kampala , Uganda antiretroviral treatment regimen include least 28 consecutive day nevirapine may eligible study . Candidates screen medical history , physical examination , blood test . Participants total approximately 5 ounce blood draw 6- 8-hour study . They come NIH clinic morning , catheter ( plastic tube ) insert arm vein collect blood . ( Alternatively , blood collect needle insert arm vein . ) Blood withdrawn accord follow schedule : - About 5 tablespoon collect upon arrival clinic overnight fast . Within 30 minute blood draw , patient breakfast take morning dose nevirapine , along medication need take time . - 1 tablespoon blood drawn 2 hour nevirapine dose . - 1 tablespoon blood drawn 4 hour later ( 6 hour nevirapine dose ) . The blood analyzed level nevirapine possibly HIV medicine . Some blood store later analysis gene ( cytochrome P450 MDR1 ) involve eliminate medicine body .</brief_summary>
	<brief_title>Differences Blood Levels Nevirapine HIV-infected Patients Uganda United States</brief_title>
	<detailed_description>The overwhelming majority HIV-infected person reside develop world . As , recent effort focus provide antiretroviral pharmacotherapy population . However , number factor indigenous non-Western HIV-infected patient may alter virologic , immunologic , and/or toxicologic response antiretroviral therapy . Absorption , distribution , clearance antiretroviral medication may differ among patient reside non-Western country secondary dietary influence , parasitic infection , malabsorption . Genetic polymorphism drug metabolize enzyme ( cytochrome P450 ; CYP ) drug transporter ( i.e . P-glycoprotein ) may also contribute altered pharmacokinetics among patient . The purpose pilot , hypothesis-generating study ( 1 ) characterize pharmacokinetics non-nucleoside reverse transcriptase inhibitor nevirapine non-Western HIV-infected population ( Kampala , Uganda ) similar cohort HIV-infected individual United States ( 2 ) compare pharmacokinetic parameter value group . Twenty-five subject site participate . Subjects Ugandan site may participate regardless CD4+ lymphocyte count viral load ; study prior U.S. cohort . The U.S. group select include subject match gender Ugandan counterpart . Subjects one pre-dose two post-dose blood sample collect determination nevirapine plasma concentration . Samples analyze use LC/MS-MS. Population pharmacokinetics parameter value ( Cmax , Cmin , AUC , CL/F , Vd ) determine use NONMEM ( Trademark ) compare group . Blood sample collect study also use determine CYP MDR1 genotype study subject effort explain observed difference pharmacokinetics parameter value study population .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Documentation patient 's medical record HIV1 infection use double ELISA second confirmatory test ( e.g. , Western Blot ) one following : detectable p24 antigen , quantifiable plasma HIV RNA , detectable proviral DNA . 2 . Males female great equal 18 year age 3 . Laboratory value within acceptable limit AST/SGOT le equal 5 time upper limit normal ( ULN ) Serum creatinine less equal 2 time ULN Hemoglobin great equal 9.0 g/dL 4 . Receipt stable nevirapinecontaining antiretroviral regimen least 28 day . 5 . Informed consent sign subject declares adherent nevirapinecontaining antiretroviral regimen . EXCLUSION CRITERIA : 1 . Presence lifethreatening unstable renal , hepatic , cardiovascular , hematologic , neurologic , psychiatric , respiratory disease , determine medical record , condition may interfere interpretation study result best interest subject opinion investigator . 2 . Laboratory value outside acceptable limit AST/SGOT less 5 time upper limit normal ( ULN ) Serum creatinine great 2 time ULN Hemoglobin le 9.0 g/dL 3 . Positive pregnancy test . 4 . Receipt IL2 within 3 month study participation . 5 . Drug alcohol use may impair safety adherence . 6 . Poor venous access . 7 . Documented report fever ( great 38.5 degree C ) within 7 day screen . 8 . Active opportunistic infection require therapy . 9 . Refusal agree allow specimen stored future research . 10 . Greater 4 loose/soft stool per day . 11 . Subject nonadherent nevirapinecontaining antiretroviral regimen and/or provide informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 28, 2011</verification_date>
	<keyword>Race</keyword>
	<keyword>Ethnicity</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Cytochrome P450</keyword>
	<keyword>Population Pharmacokinetics</keyword>
	<keyword>HIV</keyword>
</DOC>